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Background: Changes in serotonin transporter (SERT) function have been implicated in autism. SERT function is
influenced by the number of transporter molecules present at the cell surface, which is regulated by various cellular
mechanisms including interactions with other proteins. Thus, we searched for novel SERT-binding proteins and
investigated whether the expression of one such protein was affected in subjects with autism.
Methods: Novel SERT-binding proteins were examined by a pull-down system. Alterations of SERT function and
membrane expression upon knockdown of the novel SERT-binding protein were studied in HEK293-hSERT cells.
Endogenous interaction of SERT with the protein was evaluated in mouse brains. Alterations in the mRNA expression
of SERT (SLC6A4) and the SERT-binding protein in the post-mortem brains and the lymphocytes of autism patients
were compared to nonclinical controls.
Results: N-ethylmaleimide-sensitive factor (NSF) was identified as a novel SERT-binding protein. NSF was co-localized
with SERT at the plasma membrane, and NSF knockdown resulted in decreased SERT expression at the cell membranes
and decreased SERT uptake function. NSF was endogenously co-localized with SERT and interacted with SERT. While
SLC6A4 expression was not significantly changed, NSF expression tended to be reduced in post-mortem brains,
and was significantly reduced in lymphocytes of autistic subjects, which correlated with the severity of the clinical
symptoms.
Conclusions: These data clearly show that NSF interacts with SERT under physiological conditions and is required
for SERT membrane trafficking and uptake function. A possible role for NSF in the pathophysiology of autism through
modulation of SERT trafficking, is suggested.
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Autism is a pervasive developmental disorder character-
ized by severe and sustained impairment of social inter-
action and communication, and restricted or stereotyped
patterns of behavior and interest. Many studies on the
pathophysiological mechanisms of autism have focused
on the serotonergic system. Prior studies have consist-
ently found elevated serotonin levels in the whole blood
cells and platelets of autism patients [1-5] and their
relatives [6-8]. Short-term dietary depletion of tryptophan
(the precursor of serotonin) has been shown to exacerbate
repetitive behavior and to elevate anxiety and feelings of
unhappiness in autistic adults [9]. Accordingly, many
genetic studies have examined the associations between
autism and genetic mutations of human serotonin trans-
porter (SERT; solute carrier family 6 (neurotransmitter
transporter), member 4 (SLC6A4)), especially the short
allele of a polymorphism in the promoter region of the
serotonin transporter gene. Although some positive rela-
tionships have been found, the results to date are in-
consistent [10-15]. A single photon emission computed
tomography study showed that autistic children, under
light sedation, exhibit a reduction in SERT binding in the
medial frontal cortex, midbrain and temporal lobe areas
[16]. Importantly, our colleagues recently reported that
binding of SERT and its radioligand was significantly lower
throughout the brain in autistic individuals compared with
controls [17]. The reduction in the anterior and posterior
cingulate cortices was associated with an impairment of
social cognition in autistic subjects, and a significant
correlation was also found between repetitive and/or
obsessive behavior and interests and a reduction in SERT
binding in the thalamus [17]. These results suggested that
SERT protein levels and/or its transport capacity were
decreased in the brains of autistic patients. Despite this
prediction, Azmitia and colleagues reported increased im-
munoreactivity to a SERT antibody of serotonin axons in
the post-mortem cortices of autism patients [18].
SERT is an integral plasma membrane glycoprotein
that regulates neurotransmission through the reuptake
of 5-hydroxytryptamine (5-HT), also known as serotonin,
from the synaptic cleft. SERT transport capacity is known
to be regulated through mechanisms that involve subcel-
lular redistribution of the transporter, which are regulated
by various cellular mechanisms, including interactions
with other proteins [19,20]. Indeed, several SERT-binding
proteins have been reported. Syntaxin-1A [21-23] and
secretory carrier membrane protein 2 (SCAMP2) have
been reported to be associated with the N-terminal tail of
SERT [24]. Macrophage myristoylated alanine-rich C
kinase substrate (MacMARCKS) [25], integrin β3 [26] and
nitric oxide synthase (nNOS) [27] have been reported to
be associated with the C-terminal tail of SERT. SERT also
forms complexes with hydrogen peroxide-inducible clone5 protein (Hic-5) [28,29], phosphatase 2A (PP2A) [30],
and α- and γ-synuclein [31,32]. By interacting with SERT,
SCAMP2, MacMARCKS, nNOS, Hic-5, PP2A and α/γ-sy-
nuclein reduce the efficacy of serotonin reuptake because
of a reduction in surface expression of SERT or promotion
of SERT dephosphorylation [24,25,27,29-32]. Loss of inte-
grin β3 results in decreased SERT function and surface
expression in platelets [26]. Syntaxin-1A regulates the
electrophysiological properties of SERT [23].
In this study, we sought to identify novel proteins
interacting with the N- and C-terminal portions of SERT,
and which thereby regulate SERT function. We also mea-
sured the levels of mRNAs for SERT and SERT-interacting
proteins in post-mortem brains and lymphocytes from
autism patients to assess their involvement in autism.
Methods
Animal experiments
Experiments using mice were approved by the Committee
on Animal Research of Hamamatsu University School of
Medicine and University of Fukui. These experiments
were performed in accordance with the Guide for Animal
Experimentation at the Hamamatsu University School of
Medicine and the University of Fukui.
Glutathione S-transferase pull-down assays
Full-length rat SERT complementary DNA (cDNA) was
obtained from Dr Heinrich Betz (Max Planck Institute)
[25,33]. PCR fragments corresponding to the N-terminal
domain of the rat SERT (N-SERT; residues 1 to 85 amino
acids) and the C-terminal domain of the rat SERT (C-SERT;
residues 595 to 630 amino acids) were fused to glutathione
S-transferase (GST) by subcloning into the pGEX-5X-1
bacterial expression vector (Amersham Bioscience, Uppsala,
Sweden), to produce vectors containing GST-N-SERT and
GST-C-SERT. Plasmids were transformed into Escherichia
coli (BL21 (DE3), Stratagene, La Jolla, CA, USA) and were
cultured and induced with isopropyl-β-D-thiogalactopyran-
oside (IPTG) at 37°C for 4 h. Mouse brain tissue was
homogenized on ice using a homogenizer (Iuchi,
Osaka, Japan), in 5 ml of homogenization buffer
(50 mM NH4Cl, 40 mM Tris–HCl pH 8.0) supplemented
with a 1× complete protease inhibitor cocktail (Roche
Applied Science, Indianapolis, IN, USA) per brain. The
same amount of extraction buffer (20 mM NaCl, 20 mM
Tris–HCl pH 8.0, 1% NP-40, 1% deoxycholate) was added,
and homogenates were incubated at 4°C for 30 min with
rotation. Insoluble cellular debris was removed by centri-
fugation, and the supernatants were collected. Then, the
extracts were diluted up to tenfold in homogenization
buffer plus extraction buffer without detergents. Extracts
were incubated with glutathione agarose bound to GST,
GST-N-SERT or GST-C-SERT at 4°C for 3 h. Beads were
washed five times with TBS buffer (50 mM Tris–HCl
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acetic acid) and boiled in SDS-PAGE sample buffer for
5 min to elute bound proteins. These samples were
subjected to SDS-PAGE, which was followed by silver
staining using a Silver Stain MS Kit (Wako Pure
Chemical Industries, Ltd, Osaka, Japan) to visualize pro-
tein bands for mass spectrometry analysis. The samples
were also used for Western blotting experiments.
Western blot analysis
Western blotting was performed following a previously
published protocol [34]. Antibodies against SERT (1:400
to 2,000; C-20, Santa Cruz Biotechnology, Inc, CA, USA),
N-ethylmaleimide-sensitive fusion protein (NSF; 1:500;
Cell Signaling Technology, Inc, Danvers, MA, USA),
syntaxin-1A (1:500; Santa Cruz Biotechnology, Inc,
CA, USA) or β-actin (1:1,000; Abcam Inc, Cambridge, MA,
USA) were used. Immunoreactive bands were scanned and
quantified using ImageJ software (ImageJ 1.44, National
Institutes of Health, USA).
In-gel digestion and mass spectrometry analysis
Protein bands were excised from SDS-polyacrylamide
gels. The bands were processed in destaining solutions
included in the Silver Stain MS Kit. Disulfide bonds were
reduced with dithiothreitol (DTT) and the proteins were
alkylated with iodoacetamide. The proteins were then
treated with 50 μl (25 ng/μl) of Trypsin Gold (Promega,
Madison, WI, USA) in 50 mM ammonium bicarbonate
for 45 min on ice, and then overnight at 37°C. After
enzymatic digestion, the peptides were eluted from the
gel by treatment (twice, for 30 min each time) with 50 μl
of a mixture containing 50% acetonitrile and 5% trifluor-
oacetic acid. The two eluates were pooled and evaporated
to dryness in a vacuum centrifuge. Prior to mass spectro-
metric analysis, peptides were re-dissolved in 50 μl of 0.1%
formic acid. Liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) of the peptide mixtures was per-
formed on a QSTAR XL (ESI-QqTOF; AB Sciex, Foster
City, CA, USA) mass spectrometer. Product ion (MS/MS)
spectra of the peptides separated by high-performance
liquid chromatography (HPLC) were recorded and then
submitted to the Mascot database search engine (Matrix
Science [35]) for protein identification. The SwissProt
database was used with ‘all entries’ for taxonomy. The
tolerance was ±0.1 Da, and only one error was considered
for the enzyme’s cutoff point.
Production of a stable cell line (HEK293-hSERT cells)
The human SERT (hSERT) protein was transcribed from
the human SERT gene. The cDNA for hSERT was iso-
lated by RT-PCR. The PCR fragments were cloned into
pcDNA3.1(+) (Invitrogen Carlsbad, CA, USA) resulting
in the construct pcDNA-hSERT. To generate stablytransfected cells, pcDNA-hSERT was transfected into
the human embryonic kidney cell line HEK293 using
Transfectamine 2000 (Invitrogen) in accordance with the
manufacturer’s instructions. After 24 h, transfected cells
were switched to a medium containing 1 mg/ml geneticin
(G418); 1 week later, resistant colonies were isolated from
culture plates using sterile clone rings. Individual cells
were used to generate clonal lines. Multiple lines tested
positive for immunostaining using SERT Ab (Santa Cruz
Biotechnology, Inc) and a fluorescence-based uptake assay,
and clonal line #7 (termed HEK293-hSERT cells) was used
in all experiments reported here. The HEK293-hSERT
cells were cultured in DMEM (Invitrogen) supplemented
with 10% fetal bovine serum (Invitrogen), penicillin (100
U/ml), streptomycin (100 μg/ml) and G418 (0.2 mg/ml) at
37°C in 5% CO2.
Primary culture of serotonergic raphe neurons
Primary culturing of serotonergic raphe neurons was
performed using mouse neurons as described previously
[36]. Pregnant BL6 mice (E16.5) were euthanized by
cervical dislocation. Embryos were removed and placed
in Hank’s balanced salt solution (HBSS) without Ca2+
(Life Technologies Co, Carlsbad, CA, USA). Rostral raphe
neurons were dissected from the midbrain according to a
method described previously [37]. Briefly, heads were
removed from the embryos under a dissecting microscope
(SMZ645; Nikon, Tokyo, Japan), and the midbrain/brain-
stem was gently dissociated. The neural tube was opened
ventrally and flattened in a Petri dish containing HBSS
without Ca2+. A strip of tissue of approximately 0.5 mm in
width was dissected at the midline of the rostral rhomben-
cephalon. Raphe tissue was resuspended in 5 ml of HBSS
without Ca2+ and triturated ten times; the homogenate
was strained through a cell strainer (BD Biosciences,
Mississauga, ON, Canada) to remove debris, and an equal
amount of HBSS containing Ca2+ was added. Cells were
centrifuged (500 g, 5 min), and the pellet was resuspended
in 5 ml of Neurobasal media (Invitrogen) containing B27
supplement (Invitrogen), penicillin (100 U/ml), strepto-
mycin (100 μg/ml), and 0.4% L-Glutamine (Invitrogen)
and plated onto eight-well slide chambers coated with
poly-D-lysine (BD Biosciences). Two days after plating,
0.3 ml of medium from each well was replaced with fresh
medium. Cells were cultured for 7 days in vitro [36].
siRNA-mediated gene knockdown
The duplexed oligonucleotides of siRNA used in this
study were based on the sequence of the human cDNA
encoding NSF. NSF siRNAs and a non-silencing control
siRNA were obtained from Integrated DNA Technologies
(Coralville, IA, USA). The targeted sequences of the
human NSF siRNAs were as follows: 5′-GGAATGCAA
TAAAGAGTAAATATAC-3′ (siRNA-1) and 5′-GGATAG
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tion was performed using Lipofectamine RNAiMAX
(Invitrogen) in accordance with the manufacturer’s
instructions, and cells were processed 48 h after
transfection.
Immunocytochemistry and microscopy
HEK293-hSERT cells were grown on poly-D-lysine-
coated glass coverslips. Raphe neurons were plated onto
eight-well slide chambers coated with poly-D-lysine (BD
Biosciences) and cultured for 7 days in vitro [36]. Cells
were washed with PBS (−) and fixed with 2% parafor-
maldehyde in PBS (−), pH 7.4, for 15 min at room
temperature (RT). Cells were washed with PBS (−) and in-
cubated with ice cold 100% methanol for 10 min at −20°C
to permeabilize them. Cells were washed with PBS (−) and
incubated with blocking solution (5% skimmed milk in
PBS (−)) at RT for 1 h followed by incubation with
primary antibody against SERT (1:400; C-20, Santa
Cruz Biotechnology, Inc), NSF (1:500; Cell Signaling
Technology, Inc), cadherin (1:50; Abcam Inc, Cambridge,
MA, USA) or serotonin (1:50; Gene Tex, Inc, Irvine, CA,
USA) diluted in 1% skimmed milk in PBS (−) for 2 h at
RT. Cells were washed in PBS (−) and incubated with the
appropriate fluorophore-conjugated secondary antibody
diluted in 1% skimmed milk in PBS for 60 min at RT.
After washing, the cells were mounted onto microscope
slides in 50% glycerol in PBS (−). Samples were imaged
on a fluorescence microscope (BX53; Olympus, Tokyo,
Japan) or a laser scanning confocal microscope (FluoView
FV1000; Olympus).
Fluorescence-based uptake assay
The fluorescence-based uptake assay employed a fluor-
escent substrate that mimics the biogenic amine neuro-
transmitters and is taken up by the cell through their
specific transporters, resulting in increased fluorescence
intensity [38]. The corresponding fluorescence-based
potencies (FL pIC50 values) were determined in a similar
manner to the [3H]-neurotransmitter uptake protocols
[39]. HEK293-hSERT cells were plated in black, 96-well
optical bottom assay plates coated with poly-D-lysine
(#3882, Corning Life Sciences, Lowell, MA, USA) and
transfected with siRNAs as described above. Fluorescent
substrate uptake assays were performed using the Neuro-
transmitter Transporter Uptake Assay Kit (Molecular
Devices Co, Sunnyvale, CA, USA) in accordance with the
manufacturer’s instructions. Kinetic measurements of
relative fluorescence units (integrated over 0.5 ms) were
made using a cycle time of 5 min in a fluorescence micro-
plate reader (SpectraMax M5; Molecular Devices Co).
Data were normalized to cell number using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium brom-
ide (MTT) assay described below. Non-specific uptakewas determined in the presence of 10 μM fluoxetine, a
selective serotonin reuptake inhibitor.
MTT assay
Cell proliferation was measured with a MTT assay. Cells
were incubated with MTT solution at 37 ºC for 6 h. Fol-
lowing removal of the solution, dimethyl sulfoxide was
added, and the amount of formazan formed was measured
spectrophotometrically at 550 nm using a microplate
reader (Bio-Rad, Hercules, CA, USA).
Biotinylation
Biotinylation experiments were performed using the Cell
Surface Protein Isolation Kit (Pierce, Rockford, IL, USA)
in accordance with the manufacturer’s instructions. The
cells were incubated with sulfo-NHS-SS-biotin solution
for 30 min at 4°C, and the biotinylation of membrane
proteins was stopped by adding quenching solution. The
cells were washed and lysed in lysis buffer containing 1×
complete protease inhibitor cocktail (Roche Applied
Science). Cell lysates were incubated with NeutrAvidin
Agarose beads for 1 h at RT. Beads were washed and bi-
otinylated proteins were eluted using SDS-PAGE sample
buffer. Analysis was performed on aliquots taken: (a)
prior to incubation with beads (as total lysate) and (b) of
the bead elute (as the biotinylated membrane fraction).
Then, immunoblot analysis was carried out as described
above. Analysis was performed on aliquots taken: (a)
prior to incubation with beads (as total lysate) and (b) of
the bead elute (as the biotinylated membrane fraction).
Then, Western blot analysis was carried out as described
above. For the biotinylated membrane fraction, after
Western blot analysis, the membrane was stained with
Coomassie Brilliant Blue (CBB) as a protein-loading
control.
Time-controlled transcardiac perfusion cross-linking and
immunoprecipitation
The time-controlled transcardiac perfusion cross-linking
(tcTPC) experiments were performed as described previ-
ously [40]. Mice were anesthetized and perfused with
saline at 25 ml/min for 2 min to purge the blood vessels.
The perfusate was switched to fixative solution (4% for-
maldehyde in PBS (−)) at 25 ml/min and cross-linking
was carried out for 6 min. After perfusion, brains were
rapidly removed from the skull, postfixed in tcTPC
reagent and immediately frozen by immersion in liquid
nitrogen. The perfusion and postfixing procedures were
completed within 15 min. Mouse brains were homoge-
nized on ice using a homogenizer (Iuchi, Osaka, Japan),
in 5 ml of homogenization buffer (50 mM NH4Cl, 40 mM
Tris–HCl, pH 8.0) supplemented with 1× complete prote-
ase inhibitor cocktail (Roche Applied Science) per brain.
The same amount of extraction buffer (20 mM NaCl,
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was added, followed by incubation at 4°C for 30 min with
rotation. Insoluble cellular debris was removed by centri-
fugation (3,000 rpm, 10 min), and the supernatants were
then used as a brain extract. Brain extracts were pre-
cleared with 30 μl of protein G-Sepharose (Thermo Fisher
Scientific, Inc, Waltham, MA, USA) for 1 h at 4°C. Cleared
lysates were first incubated with an anti-SERT antibody
(made by two of the authors, TT and SY) at 4°C for 3 h,
and then with 20 μl of protein G-Sepharose for 1 h at RT.
The complex-bound resin was washed five times with IP
buffer (25 mM Tris–HCl, 150 mM NaCl; pH 7.2). Immu-
noprecipitated complexes were boiled in 2× SDS-PAGE
sample buffer for 5 min to elute bound proteins. Western
blot analysis was carried out as described above.
Post-mortem brain tissues
The ethics committee of the Hamamatsu University
School of Medicine approved this study. The Autism
Tissue Program (Princeton, NJ, USA) [41], the National
Institute of Child Health and Human Development’s
Brain and Tissue Bank for Developmental Disorders
(Baltimore, MD, USA) [42] and the Harvard Brain Tissue
Resource Center (Belmont, MD, USA) [43] provided fro-
zen post-mortem brain tissues from dorsal raphe regions
(n = 11 control and n = 7 autism).
Lymphocyte samples
The participants in this study were 30 male subjects with
autism spectrum disorder (ASD) and 30 healthy male
controls. All participants were Japanese. They were born
and lived in restricted areas of central Japan, including
Aichi, Gifu and Shizuoka prefectures. Based on inter-
views and available information, including hospital re-
cords, diagnoses of ASD were made by an experienced
child psychiatrist (TS) based on the DSM-IV-TR criteria.
The Autism Diagnostic Interview-Revised (ADI-R) [44]
was also conducted by two of the authors (KJT and KM),
both of whom have established reliability for diagnosing
autism with the Japanese version of the ADI-R. The
ADI-R is a semi-structured interview conducted with a
parent, usually the mother, and is used to confirm the
diagnosis and also to evaluate the core symptoms of
ASD. The ADI-R domain A score quantifies impairment
in social interaction, the domain BV score quantifies
impairment in communication, and the domain C score
quantifies restricted, repetitive and stereotyped patterns
of behavior and interests. The ADI-R domain D corre-
sponds to the age of onset criterion for autistic disorder.
The manual for the Wechsler Intelligence Scale for
Children, Third Edition [45], was used to evaluate the
intelligence quotient (IQ) of all the participants. Co-
morbid psychiatric illnesses were excluded by means of
the Structured Clinical Interview for DSM-IV (SCID).Participants were excluded from the study if they had
any symptoms of inflammation, a diagnosis of fragile X
syndrome, epileptic seizures, obsessive-compulsive dis-
order, affective disorders or any additional psychiatric or
neurological diagnoses. None of the participants had
ever received psychoactive medications before this study.
Healthy control subjects were recruited locally by adver-
tisement. All control subjects underwent a comprehen-
sive assessment of their medical history to eliminate
individuals with any neurological or other medical disor-
ders. SCIDs were also conducted to identify any personal
or family history of past or present mental illness. None
of the comparison subjects initially recruited was found
to fulfill any of these exclusion criteria.
This study was approved by the ethics committee of
the Hamamatsu University School of Medicine. All
participants as well as their guardians were given a com-
plete description of the study, and provided written infor-
med consent before enrollment. Whole-blood samples
were collected by venipuncture from all participants. Lym-
phocytes were isolated from blood samples by means of




Total RNA was isolated from the dorsal raphe regions of
post-mortem brains and lymphocytes using TRIZOL
reagent (Invitrogen). The RNA samples were further
purified using the RNeasy Micro Kit (QIAGEN, Hilden,
Germany). First-strand cDNA was synthesized from the
RNA samples using the SuperScript III First-Strand
Synthesis System (Invitrogen). Quantitative real-time
reverse-transcription polymerase chain reaction (qRT-PCR)
analysis was performed using the TaqMan method in the
ABI StepOnePlus TM Real-Time PCR System (Applied
Biosystems, Foster City, CA, USA). TaqMan assay IDs of
the genes are as follows: SLC6A4, Hs00984349_m1 and NSF,
Hs00938040_m1. Actin, beta (ACTB; Hs99999903_m1)
was used as the endogenous reference. Relative quantifica-
tion of NSF and SERT expression levels in post-mortem
brains was performed using the delta-delta CT method
[46], with the constitutively expressed gene ACTB as an
internal control. Standard curves were constructed for
NSF, SERT and ACTB primers to validate the application
of the delta-delta CT method. Relative quantification of
NSF and SERT expression levels in lymphocytes was per-
formed using the relative standard curve method, with the
constitutively expressed gene ACTB as an internal control.
Statistical analysis
The data were analyzed using a two-tailed unpaired t-test
after it had been confirmed that there were no statistically
significant differences in variance as assessed by the F test.
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Tukey’s correction was used for multiple comparisons.
One-way repeated-measures ANOVA with Tukey’s post
hoc test was used for analysis of data from the uptake
assay. The Mann–Whitney U test was used to evaluate
differences in age, post-mortem interval (PMI) and IQs
between the autism and control groups, and gene expres-
sion levels in the post-mortem brains and lympho-
cytes between these groups. Fisher’s exact test was
used to evaluate differences in race and gender be-
tween the autism and control groups. Evaluation of
the relationships between NSF expression level and
clinical variables and symptom profiles was performed
using Spearman’s rank correlation coefficient. P values
of less than 0.05 were considered to indicate statistical
significance. All statistical analyses were performed using
statistical analysis software (SPSS, version 12.0 J, IBM,
Armonk, NY, USA).
Results
Identification of N-ethylmaleimide-sensitive factor as a
novel serotonin transporter-binding protein
To identify novel binding proteins for SERT, we con-
ducted pull-down experiments using GST-N-SERT or
GST-C-SERT with and without (as a negative control)
mouse brain lysates. After SDS-PAGE and silver staining
of the gels, at least ten specific bands were observed in
the lane containing proteins eluted from GST-N-SERT
beads incubated with brain lysates, and at least three
bands were observed in the lane containing proteins
































Figure 1 Identification of NSF as a novel binding partner of SERT. (A)
(as negative controls) the mouse brain extract. Bound proteins were detect
bands were observed in the GST-N-SERT and GST-C-SERT lanes, respectively
24 peptides (in red) that matched NSF from band N-4 (in red on (A)). (C) N
analysis. C-SERT, C-terminal domain of the serotonin transporter; GST, gluta
N-terminal domain of the serotonin transporter; NSF, N-ethylmaleimide-senlysates (Figure 1A). The protein bands were excised from
the gel and subjected to in-gel trypsin digestion. The
tryptic peptide mixtures were analyzed by mass spec-
trometry. Excluding proteins that bound to both termini
of SERT, we identified seven N-terminal-specific binding
proteins, but no C-terminal-specific binding proteins
(Table 1). One of the N-terminal specific bands, migrating
at around 70 kDa, N-4 (Figure 1A), was identified as NSF,
which regulates membrane fusion events [47,48], based on
24 independent MS spectra (Figure 1B and Table 1). We
focused on the interaction between NSF and SERT in the
present study for the following reasons. First, we identified
NSF as having the highest reliability score (Table 1).
Second, NSF interacts with neurotransmitter receptors,
such as AMPA, β2 adrenergic and GABAA receptors, and
it regulates the membrane trafficking and synaptic
stabilization of these receptors [49-57]. Finally, in the
photoreceptor synapse, the NSF and Arrestin 1 inter-
action regulates expression of vesicular glutamate
transporter 1 and excitatory amino acid transporter 5
in the photoreceptor synapse [58]. These findings suggest
that NSF may interact with neurotransmitter trans-
porters and regulates these functions in the central
nervous system (CNS). To verify the interaction of
NSF with SERT, we conducted Western blot analysis.
GST, GST-N-SERT and GST-C-SERT were incubated
with mouse brain extracts. As shown in Figure 1C,
NSF bound the N-terminal region of SERT specifically. In
support of previous studies, N-terminal-specific binding







GST-N-SERT and GST-C-SERT were incubated with and without
ed by SDS-PAGE and silver staining. At least ten and three specific
, compared with negative controls. (B) Analysis using Mascot identified
-tail-specific binding of NSF to SERT was confirmed by Western blot
thione S-transferase; GST-C, GST-C-SERT; GST-N, GST-N-SERT; N-SERT,
sitive factor; MW, molecular weight.
Table 1 Identification of GST-N-SERT and GST-C-SERT pulled-down proteins from mouse brain extracts
Spot
number








N-1 Synj1 Synaptojanin 1 172,509 23 14% 785 Q8CHC4 ※ Endocytosis
N-2 Cand1 Cullin-associated NEDD8-
dissociated protein 1
136,245 14 10% 526 Q6ZQ38 ※ SCF complex assembly
N-3 Aco2 Aconitate hydratase,
mitochondrial
85,410 14 19% 534 Q99KI0
N-4 Nsf Vesicle-fusing ATPase (NSF) 82,561 24 27% 1,010 P46460 ※
N-5 Atp6v1a V-type proton ATPase
catalytic subunit A
68,283 13 21% 466 P50516 ※ Hydrolysis
N-6 Crmp1 Dihydropyrimidinase-related
protein 1
62,129 12 20% 441 P97427 ※ Axon guidance and
cell migration
N-7 Cct2 T-complex protein 1 subunit beta 57,441 11 19% 202 P80314 ※ Molecular chaperone
N-8 Fscn1 Fascin 54,474 14 25% 174 Q61553 ※ Actin filament binding
N-9 Eno1 Alpha-enolase 47,111 16 24% 703 P17182
N-10 Cnp 2′,3′-cyclic-nucleotide
3′-phosphodiesterase
47,094 22 40% 341 P16330
C-1 Aco2 Aconitate hydratase,
mitochondrial
85,410 8 9% 287 Q99KI0
C-2 Eno1 Alpha-enolase 47,111 8 20% 384 P17182
C-3 Cnp 2′,3′-cyclic-nucleotide
3′-phosphodiesterase
47,094 18 32% 225 P16330
C-SERT, C-terminal domain of the serotonin transporter; GST, glutathione S-transferase; MW, molecular weight; N-SERT, N-terminal domain of the
serotonin transporter.
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http://www.molecularautism.com/content/5/1/33Co-localization of serotonin transporter and N-
ethylmaleimide-sensitive factor in HEK293-hSERT cells
The subcellular localization of SERT and NSF was exam-
ined using immunofluorescence confocal microscopy.
NSF is expressed endogenously in HEK293 cells. We
established a stable human SERT-expressing cell line,
HEK293-hSERT, using HEK293 cells as described in the
Methods section. It was confirmed that SERT was trans-
ported to the plasma membrane in this cell line by
double staining using antibodies to SERT and cadherin,
a membrane marker (see Additional file 2: Figure S2).
HEK293-hSERT cells were double labeled with antibodies
to NSF and SERT, and it was revealed that NSF co-localized
with SERT in the plasma membrane (Figure 2A,B,C) and
intracellular particles (Figure 2D,E,F).
Effect of N-ethylmaleimide-sensitive factor knockdown on
serotonin transporter function and cellular localization
We used RNA interference to knock down endogen-
ous NSF expression. We confirmed that the efficacy of
siRNA transfection into HEK293-hSERT cells was >90%
(see Additional file 3: Figure S3). As shown in Figure 3A,B,
it was confirmed that both of the siRNAs (siRNA-1 and -2)
targeting NSF suppressed endogenous NSF protein levels
by approximately 60% (P < 0.001, one-way ANOVA with
Tukey’s post hoc test, n = 3 each). Importantly, whole-cell
SERT protein levels were not changed significantly by the
siRNAs targeting NSF (F(2,14) = 1.057; P = 0.374, one-wayANOVA, n = 5 to 6 each) (Figure 3C,D). To investigate the
effect of NSF on SERT uptake function, we conducted a
fluorescence-based uptake assay in HEK293-hSERT cells.
As shown in Figure 4, both NSF siRNAs decreased fluores-
cence uptake (siRNA-1; P = 0.005 and siRNA-2; P < 0.001,
one-way repeated measures ANOVA with Tukey’s post hoc
test, n = 8 each). Fluoxetine completely inhibited uptake
(Figure 4), including nonspecific uptake.
Next, we conducted biotinylation experiments in
HEK293-hSERT cells using sulfo-NHS-SS-biotin. This
compound, which binds to lysine and arginine residues
in proteins, is cell impermeant and labels cell-surface pro-
teins. Cells transfected with the siRNA of NSF (siRNA-2)
or a negative control were incubated with sulfo-NHS-SS-
biotin, followed by isolation of labeled proteins with avidin
beads and analysis by Western blotting using anti-SERT
antibodies. For the biotinylated membrane fraction, after
Western blot analysis, the membrane was stained with CBB
as a protein-loading control (Additional file 4: Figure S4).
As shown in Figure 5A,B, the level of SERT protein at
the cell membrane was decreased by an average of
50% (t = 5.399; df = 16; P < 0.001, two-tailed unpaired
t-test, n = 9) following NSF knockdown, despite no
change in the total levels of SERT protein (t = −1.565;
df = 10; P = 0.149, two-tailed unpaired t-test, n = 6). Finally,
we examined the distribution of SERT in HEK293-hSERT
cells when NSF was suppressed. In support of the re-




Figure 2 NSF co-localizes with SERT in HEK293-hSERT cells. (A,B,C) Double immunocytochemical staining for SERT (green) and NSF (red) in
HEK293-hSERT cells. NSF co-localizes with SERT in the cell membrane (merged). (D,E,F) High-magnification views of the regions boxed in panels
(A), (B) and (C), respectively. Arrowheads indicate double-positive intracellular particles. Scale bar: 10 μm. Results are representative of three
independent experiments. NSF, N-ethylmaleimide-sensitive factor; SERT, serotonin transporter.
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http://www.molecularautism.com/content/5/1/33membrane expression of SERT was decreased by NSF
knockdown in HEK293-hSERT cells (Figure 5C).
Association between serotonin transporter and
N-ethylmaleimide-sensitive factor in vivo
To determine the physiological significance of our findings
in vivo, we examined: (a) the interaction between SERT
and NSF in the mouse brain by immunoprecipitation and
Western blotting and (b) the cellular distributions of NSF
and SERT in cultured mouse raphe neurons by immuno-
cytochemistry and microscopy.
Schmitt-Ulms and colleagues have established a method
that covalently conserves protein interactions through
tcTPC [40]. This method enables the preservation of pro-
tein–protein interactions that occur under physiological
conditions. We investigated the interaction of SERT with
NSF in the mouse brain using this tcTPC method. First,
we examined the accuracy of the method. Total protein
from non-tcTPC- or tcTPC-treated mouse brains was an-
alyzed by immunoblotting, and we confirmed that SERT-
containing cross-linked complexes were retained by this
method (see Additional file 5: Figure S5A). Second, we
checked whether the complexes were precipitated by anti-
SERT antibodies and confirmed that SERT-containing
cross-linked complexes were precipitated in a dose-
dependent manner using this antibody (see Additional
file 5: Figure S5B). Then, finally, we investigated the
binding of SERT to NSF. As shown in Figure 6A, NSF co-
immunoprecipitated with SERT from tcTPC-treated
brain cells indicating that NSF interacts with SERT inthe mouse brain under physiological conditions. Next,
the cellular distributions of NSF and SERT in cultured
mouse raphe neurons were examined. About 10% of all
cultured cells were 5-HT-positive neurons in support of a
previous report (data not shown) [36]. NSF was ubiqui-
tously expressed in all cultured cells (data not shown). As
shown in Figure 6B, triple immunocytochemical staining
for SERT, NSF and 5-HT revealed that NSF co-localizes
with SERT in the cell body and fibers of cultured seroto-
nergic neurons.
SLC6A4 and N-ethylmaleimide-sensitive factor expression
in the raphe region of post-mortem brains from autism
patients
The demographic characteristics of subjects (seven with
autism and eleven control subjects) are described in
Tables 2 and 3. There were no significant differences in
age (P = 1.000, Mann–Whitney U test), race (P = 0.305,
Fisher’s exact test), gender (P = 0.596, Fisher’s exact test)
and PMI (P = 0.513, Mann–Whitney U test) between the
autism and control groups (Table 3). Although changes
in SERT function and expression have been implicated
in autism, mRNA expression of the SLC6A4 gene that
encodes SERT in the brains of autistic individuals
has never been reported. Therefore, first, we measured
SLC6A4 expression in the raphe region of post-mortem
brains from autistic individuals and controls using qRT-
PCR. SLC6A4 expression was normalized to the expres-
sion levels of an internal control (ACTB). As shown in
Figure 7A, there are wide individual differences in the
Figure 3 Knockdown efficiency of NSF siRNAs and effect on expression level of SERT in HEK293-hSERT cells. Two siRNAs targeting
specific NSF sequences were transfected into HEK293-hSERT cells. (A) The expression levels of NSF and β-actin (as an internal control) were
assayed by immunoblot analysis. (B) Quantitation of relative band densities for NSF was performed by scanning densitometry. Data are expressed
as the means ± standard deviation, n = 3. ***P < 0.001 vs internal control (one-way ANOVA with Tukey’s post hoc test). (C) The expression levels of
SERT and β-actin (as an internal control) were assayed by immunoblot analysis. (D) Quantitation of relative band densities for SERT was performed
by scanning densitometry. Data are expressed as the means ± standard deviation, n = 5 or 6. NSF, N-ethylmaleimide-sensitive factor; SERT,
serotonin transporter; siRNA, small interfering RNA.
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http://www.molecularautism.com/content/5/1/33expression level of SLC6A4 among the subjects, and the
level did not differ significantly between subjects with
autism and controls (P = 0.928, Mann–Whitney U test).
Then, we measured NSF expression in the same way. NSF
expression was normalized to the expression of ACTB.
We found that the NSF expression level in autism patients
tended to be lower than that in controls; however, this
trend was not statistically significant (P = 0.069, Mann–
Whitney U test) (Figure 7B).
SLC6A4 and N-ethylmaleimide-sensitive factor expression in
lymphocytes from patients with autism spectrum disorders
NSF is expressed ubiquitously in all normal human
tissues including lymphocytes [59]. Lymphocytes alsocarry SERT [60]. Thus, we measured expressions of
these genes in lymphocytes from individuals with ASD
and age- and sex-matched controls by qRT-PCR. The
demographic characteristics of the subjects (30 with
ASD and 30 control subjects) are described in Table 4.
There were no significant differences in age (P = 0.928,
Mann–Whitney U test) or IQs (verbal IQ, P = 0.098,
Mann–Whitney U test; performance IQ, P = 0.076, Mann–
Whitney U test; full-scale IQ, P = 0.554, Mann–Whitney U
test) between the ASD and control groups (Table 4). As
shown in Figure 8A, the expression level of SLC6A4 did
not differ significantly between subjects with ASD and
controls (P = 0.518, Mann–Whitney U test). On the other

























Figure 4 NSF knockdown results in decreased uptake function
of SERT in HEK293-hSERT cells. Fluorescent substrate uptake
activity was significantly decreased in HEK293-hSERT cells transfected
with siRNAs targeting specific NSF sequences, siRNA-1 (◆) and
siRNA-2 (▲), compared with negative control (○) (control vs siRNA-1
P < 0.01, and control vs siRNA-2 P < 0.001, one-way repeated measures
ANOVA with Tukey’s post hoc test). Nonspecific uptake was determined
in the presence of 10 μM fluoxetine (■). Data are expressed as a
percentage of the control level. Each point corresponds to the
mean ± standard deviation, n = 8. siRNA, small interfering RNA.
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http://www.molecularautism.com/content/5/1/33patients were significantly lower than that in controls
(P = 0.0011, Mann–Whitney U test) (Figure 8B). More-
over, there was a significantly negative correlation between
NSF expression and ADI-R Domain A score, which quan-
tified impairment in social interaction, in individuals with
ASD (rs = 0.131, P = 0.0498, Spearman’s rank correlation
coefficient test) (Figure 8C). There were no significant
correlations between NSF expression levels and levels of
SLC6A4 and any other symptom profile or clinical vari-
ables (data not shown).
Discussion
In this study, NSF was identified as a novel SERT-
binding protein interacting with the N-terminal region
of SERT. NSF knockdown resulted in decreased mem-
brane expression of SERT and decreased uptake of sub-
strate. These results clearly show that NSF modulates
SERT membrane trafficking, which is consistent with its
uptake function. An immunoprecipitation assay using
mouse brain and immunocytochemistry of cultured
mouse raphe neurons clearly indicated that SERT–NSF
complexes were formed under physiological conditions
in vivo. In addition, a study of post-mortem brains re-
vealed that the SLC6A4 expression level was not affected
in subjects with autism, but the NSF expression level in
the raphe region tended to be decreased; however, this
potential trend is not statistically significant. In lympho-
cytes, the SLC6A4 expression level was also unchanged,but the NSF expression level was significantly decreased
in subjects with ASD and correlated with the severity of
clinical symptoms.
N-ethylmaleimide-sensitive factor functions and protein
binding
NSF is a homohexameric ATPase [61,62], which is an
essential component of the protein machinery respon-
sible for various membrane fusion events, including
intercisternal Golgi protein transport and the exocytosis
of synaptic vesicles [63]. NSF binds to soluble NSF
attachment protein–receptor (SNARE) complexes and
mediates the recycling of spent SNARE complexes for
subsequent rounds of membrane fusion [63,64]. While
this is a major function of NSF, it also interacts with
receptor proteins, such as AMPA, β2 adrenergic and
GABAA receptors, and is thought to affect their trafficking
patterns or recycling [49-57]. Additionally, an interaction
between NSF and arrestin 1 regulates the expression
of vesicular glutamate transporter 1 and excitatory amino
acid transporter 5 in the photoreceptor synapse [58]. In
the present study, we found, for the first time, that NSF
binds the neurotransmitter transporter SERT and regu-
lates its function in the CNS.
Serotonin transporter forms complexes with N-
ethylmaleimide-sensitive factor in vivo
Several putative SERT-binding proteins have been repor-
ted [21-32]. However, almost all of these were identified
using the yeast two-hybrid system and little is known
regarding whether any of these proteins bind to SERT
and regulate its function in the mammalian brain. Also,
little is known about the involvement of these proteins
in autism [65,66]. Therefore, in this study, we used a
pull-down system together with mouse brain tissue to
identify novel SERT-binding proteins. Moreover, we used
the tcTPC method, which is an innovative tool for study-
ing proteins in living tissues [40]. This method enabled
us to preserve protein–protein interactions occurring
under physiological conditions. This cross-linking also
preserves membrane protein assemblies, which are
degraded by solubilizing detergents. For instance,
whereas most detergents cause rapid disintegration of
the γ-secretase complex, three of four known components
of the complex were purified and identified from harsh
detergents and a high salt concentration by tcTPC [40].
Because NSF was not co-immunoprecipitated with SERT
from non-tcTPC-treated brains (Figure 6A), it is likely
that SERT–NSF complexes are sensitive to solubilizing
detergents. The discovery of complexes including NSF
and SERT, which form in the mammalian brain under
physiological conditions, in the present study, is important
from the viewpoint of their potential involvement in the
pathophysiology of disorders such as autism. It is not yet
Figure 5 (See legend on next page.)
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(See figure on previous page.)
Figure 5 NSF knockdown results in decreased SERT expression at the plasma membrane in HEK293-hSERT cells. (A) Biotinylation
experiments in HEK293-hSERT cells transfected with siRNA-2 targeting a specific NSF sequence or negative control. Transfected cells were
incubated with sulfo-NHS-SS-biotin, and labeled proteins were analyzed by immunoblotting using anti-SERT antibodies. (B) Quantitation of relative
band densities for SERT was performed by scanning densitometry. Data are expressed as the means ± standard deviation, n = 6 to 9. ***P < 0.001 vs
negative control (two-tailed unpaired t-test). (C) Double immunocytochemical staining for SERT (green) and NSF (red) in HEK293-hSERT cells transfected
with control siRNA (upper panels) and siRNA for NSF (siRNA-2, lower panels). Scale bar: 10 μm. Results are representative of three independent
experiments. NSF, N-ethylmaleimide-sensitive factor; SERT, serotonin transporter; siRNA, small interfering RNA.
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http://www.molecularautism.com/content/5/1/33clear whether NSF binds SERT directly or indirectly. In
addition, the band for the SERT–NSF complex was
smeared, suggesting that multiple types of SERT–NSF
complexes exist. It is possible that SERT interacts with
NSF through other proteins. Indeed, it is possible that
GABAA receptors interact with NSF via GABAA receptor-
associated protein, and regulate its intracellular distribu-
tion and recycling [56,67]. Detailed analyses of these










Figure 6 NSF interacts with SERT in vivo. (A) Interaction of SERT with N
tcTPC-treated mouse brains (as input, lanes 1 and 2, respectively). Proteins fro
with SERT antibodies (lane 3 and 4), and the resulting immunoblot was probe
brains, SERT–NSF complexes and free NSF were identified (lane 4). Results are
with SERT in primary cultures of mouse raphe nuclei neurons. Triple immunoc
primary cultures of mouse raphe nuclei neurons. The third panel (merged) sh
nuclei neurons. These neurons are 5-HT-positive serotonergic neurons (as sho
three independent experiments. 5-HT, 5-hydroxytryptamine; IB, immunoblotti
mide-sensitive factor; SERT, serotonin transporter; tcTPC, time-controlled transSerotonin transporter and N-ethylmaleimide-sensitive
factor expressions in autism
Recently, Nakamura and colleagues reported that the
levels of SERT based on its radioligand binding were
significantly lower throughout the brain in autistic indi-
viduals compared with controls [17]. On the other hand,
Azmitia and colleagues reported increased immunoreac-
tivity to a SERT antibody of serotonin axons in the post-







SF in mouse brain. Immunoblot of total proteins from non-tcTPC- and
m non-tcTPC- or tcTPC-treated mouse brains were immunoprecipitated
d for NSF. In immunoprecipitated samples using tcTPC-treated mouse
representative of three independent experiments. (B) NSF co-localizes
ytochemical staining for SERT (green), NSF (red) and 5-HT (blue) in
ows that NSF co-localizes with SERT primary cultures of mouse raphe
wn in the fourth panel). Scale bars: 10 μm. Results are representative of
ng; IP, immunoprecipitation; MW, molecular weight; NSF, N-ethylmalei-
cardiac perfusion cross-linking.
Table 2 Information for post-mortem brain tissues
Sample ID Diagnosis Age (years) Gender Post-mortem interval (hours) Race Cause of death
1065 Control 15 M 12 Caucasian Multiple injuries
1297 Control 15 M 16 African-American Multiple injuries
1407 Control 9 F 20 African-American Asthma
1541 Control 20 F 19 Caucasian Head injuries
1708 Control 8 F 20 African-American Asphyxia, multiple injuries
1790 Control 14 M 18 Caucasian Multiple injuries
1793 Control 12 M 19 African-American Drowning
1860 Control 8 M 5 Caucasian Cardiac arrhythmia
4543 Control 29 M 13 Caucasian Multiple injuries
4638 Control 15 F 5 Caucasian Chest injuries
4722 Control 14 M 16 Caucasian Multiple injuries
797 Autism 9 M 13 Caucasian Drowning
1638 Autism 20 F 50 Caucasian Seizure
4231 Autism 8 M 12 African-American Drowning
4721 Autism 8 M 16 African-American Drowning
4899 Autism 14 M 9 Caucasian Drowning
5000 Autism 27 M 8.3 NA NA
6294 Autism 16 M NA NA NA
F, female; M, male; NA, not available.
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the raphe region of post-mortem brains from subjects
with autism. Our findings and previous results lead us to
two suggestions. First, although the transcription of
SLC6A4 is normal in subjects with autism, the level of
SERT protein at the pre-synaptic membrane is decreased
because of an impairment of the trafficking system.
Second, SERT protein that is not delivered to the pre-
synaptic membrane accumulates in axon fibers in the
brains of subjects with autism. In lymphocytes, we found
that SLC6A4 expression was not changed in subjects
with ASD. In contrast with our finding, Hu et al. previ-
ously reported that there was a significant decrease in
the expression in the more severely affected twin for
autistic twin pairs studied using lymphoblastoid cell lines
[68]. This study used lymphoblastoid cell lines, not
lymphocytes, from only three sets of discordant twins,
and SLC6A4 expression was not compared with normalTable 3 Demographic data associated with raphe brain-tissue
Control (n = 11)
Age (years) (range) 14.45 (8–29)
Race, n (%) Caucasian 7 (63.6), African-American 4
Gender, n (%) Male 7 (63.6), Female 4 (36.4)
Post-mortem interval (hours) (range) 14.82 (5–20)
aDerived from Mann–Whitney U test, bDerived from Fisher’s exact test.
NA, not available; NS, not significant.controls [68]. These differences may be the cause of the
discrepancies between the present study and that report.
We found that the NSF expression levels tended to de-
crease in the raphe region of post-mortem brains from
subjects with autism; however, this trend was not statisti-
cally significant (n = 11 control and n = 7 autism). Further
studies with larger numbers of post-mortem brains are
needed to clarify NSF expression status in the brain of aut-
ism patients. In lymphocytes, we found, for the first time,
that NSF expression was significantly lower in subjects
with ASD and lower NSF expression correlated with the
severity of impairments in social interaction. Our findings
suggest that peripheral NSF mRNA levels may serve as a
reliable peripheral biological marker of ASD.
Sullivan et al. reported that the expression levels of a
number of biologically relevant genes are statistically
similar between lymphocytes and CNS tissues including
the brain, and suggested that the cautious and thoughtfulsamples
Autism (n = 7) P value
14.57 (8–27) NSa
(36.4) Caucasian 3 (42.9), African-American 2 (28.6), NA 2 (28.6) NSb

















































Figure 7 SLC6A4 and NSF expression in the raphe region of post-mortem brains. Comparison of SLC6A4 (A) and NSF (B) expression levels
in the raphe region of post-mortem brains from control and autistic subjects. The Mann–Whitney U test was used to compare gene expression
levels between autism and control groups. Data are presented as the means ± standard error of the mean. n = 11 control and n = 7 autism. NSF,
N-ethylmaleimide-sensitive factor.
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http://www.molecularautism.com/content/5/1/33use of lymphocytic gene expression may be a useful sur-
rogate for gene expression in the CNS when it has been
determined that the gene is expressed in both [69]. In
support of previous findings [59,60], the expressions of
SLC6A4 and NSF were detected in both tissues, and it is
likely that levels of SLC6A4 and NSF in the peripheral
lymphocytes may reflect the levels in post-mortem brains,
although further study is needed.
The serotonin transporter–N-ethylmaleimide-sensitive
factor binding and implications for pathophysiology in
autism
Sanyal and Krishnan reported a lethal mutation in the
Drosophila homolog of NSF [70]. Intriguingly, mutant
adult survivors show abnormal seizure-like paralytic
behavior [70]. Additionally, Matveeva and colleagues
reported that decreased production of NSF is associated
with epilepsy in rats [71]. Importantly, a high rate of co-Table 4 Demographic data associated with lymphocyte samp
Control (N = 30)b







Verbal IQ 99.1 ± 10.3 (77–120)
Performance IQ 97.0 ± 10.2 (76–114)
Full-scale IQ 97.8 ± 9.5 (82–115)
aDerived from Mann–Whitney U test; bvalues are expressed as mean ± standard dev
ADI-R, Autism Diagnostic Interview-Revised; IQ, intelligence quotient; NS, not signifioccurrence of autism and epilepsy has been described
[72-76]. Approximately 30% of children with autism
have epilepsy and 30% of children with epilepsy have
autism [77]. Interestingly, an abnormal status for SERT
has been reported in epileptic patients as follows. Auto-
radiography experiments have revealed that the temporal
neocortex surrounding the epileptic focus of patients
with mesial temporal lobe epilepsy presents diminished
SERT binding in all cortical layers [78]. A significant de-
crease was found in the SERT density in the platelet
membranes from epileptic patients having undergone an
epileptic seizure [79,80]. Additionally, it has been shown
that epileptic patients who had been treated with in-
hibitors of serotonin reuptake, such as fluoxetine and
citalopram, in addition to their ongoing antiepileptic
therapy displayed remarkable clinical improvements
[81,82]. This indirect evidence implies the relationship
between SERT and NSF in neurological disorders, suchles
Autism (N = 30)b P value
11.6 ± 2.7 (7–16) NSa
20.0 ± 5.3 (10–30)
14.3 ± 4.0 (8–23)
8.5 ± 3.4 (3–9)
3.1 ± 1.1 (1–5)
90.4 ± 28.7 (44–153) NSa
89.8 ± 22.9 (47–131) NSa
89.0 ± 26.9 (42–140) NSa
iation (range).











































































Figure 8 SLC6A4 and NSF expression in lymphocytes. Comparison of SLC6A4 (A) and NSF (B) expression levels in lymphocytes from control
and ASD subjects. The Mann–Whitney U test was used to compare gene expression levels between autism and control groups. Data are
presented as the means ± standard error of the mean. n = 30 control and n = 30 autism. The NSF expression levels in ASD patients were significantly
lower than in controls (P = 0.0011). (C) Correlation between lymphocyte NSF expression levels and Autism Diagnostic Interview-Revised (ADI-R) domain
A scores in autistic subjects. There was a negative correlation between lymphocyte NSF expression levels and ADI-R domain A scores (rs = 0.131,
P = 0.0498), n = 30 autism. ADI-R, autism diagnostic interview-revised; NSF, N-ethylmaleimide-sensitive factor.
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NSF binding in the brain of autism patients would be
useful for understanding the mechanisms that underlie
autism. In addition, an animal model, such as an NSF
conditional knockout mouse, would be a useful tool for
understanding the mechanisms that underlie ASD.
As mentioned above, NSF interacts with neurotrans-
mitter receptors such as AMPA, β2 adrenergic and
GABAA receptors, and regulates the membrane traffick-
ing and recycling of these receptors [49-57]. An abnor-
mal status of many of these receptors has been reported
in autism. Binding of GABAAα5 and its radioligand was
significantly lower throughout the brains of participants
with ASDs compared with controls [83]. The mRNA levels
of AMPA receptor were significantly increased in the
post-mortem cerebellum of autistic individuals, while the
receptor density was slightly decreased in people with
autism [84]. It is possible that NSF may contribute to the
pathophysiology of autism through these known interac-
tions with relevant molecules.Conclusions
This study showed that dysfunctional trafficking of SERT
mediated by NSF may be linked with the pathophy-
siology of autism. The identification of SERT-binding
proteins provides new opportunities not only to dissect
the accessory components involved in SERT function
and regulation, but also to elucidate the pathophysiology
of psychiatric disorders or developmental disorders, such
as autism. Future studies should examine the patho-
physiological implications of SERT–NSF interactions for
autism.Additional files
Additional file 1: Figure S1. N-tail-specific binding of syntaxin-1A to
SERT was confirmed by Western blot analysis.
Additional file 2: Figure S2. SERT is transported to the plasma
membrane in HEK293-hSERT cells. (A, B) Double immunocytochemical
staining for SERT (green) and the membrane maker cadherin (red) in
HEK293-hSERT cells. (C) SERT was mainly co-localized with the membrane
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http://www.molecularautism.com/content/5/1/33maker (cadherin) (merged). Scale bar: 10 μm. Results are representative of
three independent experiments.
Additional file 3: Figure S3. Transfection efficacy of siRNA in HEK293-
hSERT cells. We determined the proportion of siRNA-transfected HEK293-
hSERT cells using a commercially available fluor-oligo kit (TYE 563 DS,
Integrated DNA Technologies). The proportion of siRNA-transfected cells
was 90%. Upper panels show untreated cells and lower panels show red
fluorescent oligo-transfected cells. Left panels show phase-contrast
images and right panels show the images obtained by fluorescence
microscopy (excitation: 546 nm, emission: 590 nm). Scale bar: 50 μm.
Results are representative of three independent experiments.
Additional file 4: Figure S4. CBB staining of membranes from
biotinylated fractions. Biotinylation experiments in HEK293-hSERT cells
transfected with siRNA-2 targeting a specific NSF sequence or negative
control. Transfected cells were incubated with sulfo-NHS-SS-biotin.
After Western blot analysis, the membrane was stained with CBB as a
protein-loading control.
Additional file 5: Figure S5. Confirmation of tcTPC efficacy. (A)
Western blotting of total proteins from non-tcTPC- or tcTPC-treated
mouse brains (lanes 1 and 2, respectively) using anti-SERT antibodies.
Results are representative of three independent experiments. It was
confirmed that SERT-containing cross-linked complexes were retained by
the tcTPC method (lane 2). (B) Proteins from non-tcTPC- or tcTPC-treated
mouse brains were immunoprecipitated with rat immunoglobulin G (IgG)
as a negative control (lanes 1 and 5) and SERT antibodies (lanes 2 to 4
and 6 to 8), and the resulting Western blot was probed for SERT. In
immunoprecipitated samples using tcTPC-treated mouse brains,
SERT-containing cross-linked complexes were identified (lanes 6 to 8) in a
dose-dependent manner. Results are representative of three independent
experiments.Abbreviations
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